Skip to main content
Clinical trial efficacy data
Navbar Image
Clinical trial efficacy data
This site is intended only for US healthcare professionals.

Clinical trial efficacy data

Reduced risk of anemia in clinical trials1-3

  • Fewer red blood cell-related events from chemotherapy in patients taking COSELA in clinical trials, including1-4:
    • Grade 3/4 decreased hemoglobin (secondary and exploratory endpoints)
    • Red blood cell transfusions after week 5 (secondary and exploratory endpoints)
    • ESA administration (secondary and exploratory endpoints)
  • COSELA administration can cause injection-site reactions, including phlebitis and thrombophlebitis

1L=first-line; 2L=second-line; 3L=third-line; ESA=erythropoiesis-stimulating agent.

a
Adjusted relative risk=0.642 (95% CI: 0.294, 1.404).1
b
Adjusted relative risk=0.663 (95% CI: 0.336, 1.310).4
c
Adjusted relative risk=0.529 (95% CI: 0.145, 1.927).4
d
Study 2 was a proof-of-concept study with the primary objectives of assessing safety and tolerability; efficacy objectives were secondary or exploratory.2